Portfolio

Axovan AG
Pharmaceuticals
Switzerland
www.actelion.com

Axovan AG was a drug development company specializing in G Protein-Coupled Receptors (GPCRs).

The company had a fully functional drug discovery platform and a growing portfolio of drug candidates targeting GPCRs for various indications.

In 2003 Axovan was acquired by Actelion Pharmaceuticals Ltd, a company publicly traded on the Swiss Stock Exchange (SIX:ATLN) and a previous NeoMed Innovation II portfolio company.


Status: Realised

Contact person: Claudio Nessi



Back to our portfolio

Investment

NeoMed identified Axovan AG as an attractive investment opportunity in 2002 and had early access to the opportunity through personal contacts and network in Switzerland. 

NeoMed acted as co-lead investor pricing the Series B financing round.

As a board director, NeoMed played an active role in the strategic development of the company and played a key role in the trade sale negotiations especially as many board members were conflicted.

NeoMed sold its shares in a trade sale to Actelion Pharmaceuticals Ltd in 2003.